Progressive relapsing multiple sclerosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Progressive relapsing multiple sclerosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety of Tolebrutinib for Patients with Relapsing or Progressive Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-for-patients-with-relapsing-or-progressive-multiple-sclerosis/ Mon, 04 May 2026 07:51:25 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-for-patients-with-relapsing-or-progressive-multiple-sclerosis/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called Tolebrutinib in individuals with different types of Multiple Sclerosis (MS). Multiple Sclerosis is a disease that affects the nervous system, and this study includes participants with relapsing MS, primary progressive MS, and non-relapsing secondary progressive MS. The medication being tested, Tolebrutinib, is taken in the form of film-coated tablets. The study also involves the use of a placebo, which is a substance with no active medication, to compare the effects of Tolebrutinib.

The purpose of this study is to determine how safe and tolerable Tolebrutinib is over a long period. Participants will take the medication orally, and the study will last for up to 36 months. During this time, researchers will monitor participants for any adverse events, which are unwanted effects that may occur during the study. The study will also look at how the medication affects the progression of disability in participants with MS and track any changes in the brain using Magnetic Resonance Imaging (MRI), a type of scan that provides detailed images of the brain.

In addition to Tolebrutinib, the study involves other substances like Anhydrous Cholestyramine, which is used to bind certain substances in the intestines, and Magnetic Resonance Imaging Contrast Media, which helps improve the clarity of MRI images. These substances are used to support the study’s objectives and ensure accurate monitoring of the participants’ health. The study aims to provide valuable information on the long-term use of Tolebrutinib in managing Multiple Sclerosis.

]]> Study on the Effects of Ozanimod on Inflammation in Patients with Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-the-effects-of-ozanimod-on-inflammation-in-patients-with-relapsing-multiple-sclerosis/ Wed, 29 Apr 2026 14:58:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ozanimod-on-inflammation-in-patients-with-relapsing-multiple-sclerosis/ This clinical trial is focused on studying the effects of a medication called ozanimod on a condition known as Multiple Sclerosis (MS). MS is a disease that affects the brain and spinal cord, leading to symptoms like fatigue, difficulty walking, and vision problems. The study specifically looks at types of MS that have periods of worsening symptoms followed by recovery, known as Relapsing Multiple Sclerosis. The medication being tested, ozanimod, is taken as a capsule and is also known by the code name RPC1063.

The purpose of the study is to understand how ozanimod affects inflammation in the brain, particularly in areas called the meninges, which are the protective layers around the brain and spinal cord. The study will also look at how the medication impacts certain cells in the brain called glial cells, which support and protect nerve cells. Participants in the study will take ozanimod for one year, and researchers will monitor changes in specific proteins and markers in the body that are related to inflammation and nerve damage. These markers will be measured in the cerebrospinal fluid (CSF), which is the fluid surrounding the brain and spinal cord, and in the blood.

Throughout the study, participants will undergo various tests, including MRI scans, to observe any changes in the brain’s structure and the presence of lesions, which are areas of damage. The study aims to provide insights into how ozanimod can help manage MS by reducing inflammation and protecting nerve cells, potentially leading to better treatment options for people living with this condition.

]]> Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-and-teriflunomide-for-patients-with-multiple-sclerosis/ Wed, 29 Apr 2026 14:29:39 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-and-teriflunomide-for-patients-with-multiple-sclerosis/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called tolebrutinib in people with different types of Multiple Sclerosis (MS). MS is a disease that affects the nervous system, and it can be categorized into several types, including relapsing multiple sclerosis (RMS), primary progressive multiple sclerosis (PPMS), and nonrelapsing secondary progressive multiple sclerosis (NRSPMS). The purpose of this study is to understand how safe and tolerable tolebrutinib is for people with these conditions over a long period.

Participants in this study will receive tolebrutinib, which is taken as a film-coated tablet, or a placebo. The study will also involve the use of another medication called Aubagio, which contains the active substance teriflunomide. Some participants may receive a placebo that matches the appearance of Aubagio. The study will monitor participants for any side effects or adverse events that may occur while taking these medications. Additionally, the study will track changes in the participants’ condition, such as the progression of disability or the rate of relapses in those with RMS.

The study will last for several years, allowing researchers to gather comprehensive data on the long-term effects of tolebrutinib. Participants will be regularly assessed to ensure their safety and to evaluate the effectiveness of the treatment. The study aims to provide valuable insights into the management of multiple sclerosis and to improve treatment options for those living with this condition.

]]>